Objectives Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized
by dry cough, fatigue, and progressive exertional dyspnea. Lung parenchyma and …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung
disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are …

Abstract Background and Objective Idiopathic pulmonary fibrosis (IPF) is characterized by
progressive lung fibrosis of unknown aetiology. Epidemiological studies have suggested …

Background Nutritional status impacts quality of life and prognosis of patients with
respiratory diseases, including idiopathic pulmonary fibrosis (IPF). However, there is a lack …

The last 2 years have presented previously unforeseen challenges in pulmonary medicine.
Despite the significant impact of the SARS‐CoV‐2 pandemic on patients, clinicians and …

Background Sarcopenia gained importance in the evaluation of patients with chronic
respiratory diseases, including idiopathic pulmonary fibrosis (IPF), since it may impact …

Background Currently, there are two antifibrotics used to treat idiopathic pulmonary fibrosis
(IPF): pirfenidone and nintedanib. Antifibrotics slow disease progression by reducing the …

The identification of novel prognostic biomarkers might enhance individualized
management strategies in patients with idiopathic pulmonary fibrosis (IPF). Although several …

Objectives Sarcopenia is a syndrome characterized by reduced muscle mass and function. It
is well-recognized as a complication in chronic diseases such as chronic obstructive …

Body composition and muscle strength are emerging aspects in idiopathic pulmonary
fibrosis (IPF) clinical assessment. We aimed to study the relationships of handgrip strength …